Search Results

You are looking at 31 - 40 of 452 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

offer surgical treatment and more likely to use induction therapy before resection, whereas European surgeons preferred to offer OP followed by adjuvant therapy in select cases of N2 disease. Different therapeutic methods were compared in previous

Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

patients with very low risk WT, as described in the text, who were candidates to receive no adjuvant therapy. The structure of the AREN ‘0’ studies is depicted in Figure 2 . An expanded menu of biologic and clinical prognostic factors, including

Full access

Eric Jonasch

Center, and Vice Chair of the NCCN Guidelines Panel for Kidney Cancer, as he introduced his presentation at the NCCN 23rd Annual Conference. Adjuvant Therapy Five adjuvant therapy trials have been conducted in renal cell carcinoma (RCC). The ASSURE

Full access

Louis Burt Nabors

different: for RTOG 9402, neoadjuvant therapy consisted of PCV chemotherapy before RT, and in EORTC 26951 adjuvant therapy consisted of PCV chemotherapy after RT. However, toxicity from the PCV regimen was an issue in both studies. “A lot of patients did not

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–1717. Breast Cancer Mortality Figure 3 shows age-specific breast cancer incidence rates in the United States from the SEER database for 1975 to 2003 for women aged 40

Full access

Presenter: Eileen M. O’Reilly

pembrolizumab to maintenance olaparib, with arms stratified by mutation profile and exceptional response to platinum therapy. Adjuvant Therapy: Overall Survival Advantage Proven Based on the phase III PRODIGE 24/CCTG PA.6 trial, the state-of-the-art adjuvant

Full access

Christopher A. Barker and April K. Salama

also noted that immunotherapies that are robust in the advanced disease setting are now proving their worth as adjuvant treatment. Several effective options are now approved for adjuvant therapy besides observation. Nivolumab is now preferred over

Full access

Michael D. Green and James A. Hayman

the primary site . JAMA Dermatol 2016 ; 152 : 1001 – 1007 . 21. Fields RC Busam KJ Chou JF . Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma . Cancer 2012 ; 118

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

– 14 Thus, in these high-risk patients, it would seem reasonable to offer SLNB to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. NCCN Guidelines Insights : Metastatic Colon Cancer, Version